LDN Website Update - March 20, 2010

March 20, 2010

LATEST NEWS AS OF MARCH 2010

[Note: for the complete version of this information, with active links, please

Successful LDN for MS Trial Published by UCSF Physicians

Bruce Cree, MD and co-researchers at the Multiple Sclerosis Center at University

of California, San Francisco, published their study " Pilot Trial 0f Low Dose

Naltrexone and Quality of Life in MS " in the online journal of the ls of

Neurology on February 19, 2010. Some 80 patients with MS were involved in this

double-blind, " randomized, placebo-controlled, crossover-design study of the

effects of low dose naltrexone on quality of life as measured by the multiple

sclerosis quality of life inventory. " Each subject received either LDN 4.5 mg

nightly or a placebo for 8 weeks, followed by one week without either, and then

a further 8 weeks on the the alternate capsule. The results revealed that LDN

use led to " significant improvement " in a series of mental health quality of

life measures within two months. The authors reported that the medication was

" well tolerated and serious adverse events did not occur " , and that they felt

" [f]urther studies with LDN in MS are warranted. " (See Clinical Trials for LDN /

Recently Published.)

Phase II of LDN for Crohn's Complete; Early Results in May

Dr. Jill , Professor of Gastroenterology at Pennsylvania State University's

College of Medicine, has now completed her NIH-supported Phase II study of LDN

for Crohn's disease, which involved 40 adults, and is readying it for

publication. Dr. intends to make the general outcomes known in an oral

presentation during the first week in May 2010 at the Digestive Disease Week

meetings at the New Orleans Convention Center. She remains very optimistic about

the usefulness of LDN for inflammatory bowel diseases, such as Crohn's disease.

(See Clinical Trials for LDN / In Progress.)

OTHER WEBSITE CHANGES

Changes to the website include improved and expanded navigation links on every

page, LDN user quotations at the top of the homepage, and updates to the

Clinical Trials page.

LDN Website Editors

email@...

Recommended Posts